Olaparib OK'd for Metastatic Breast Ca with Mutated BRCA
Related Biotechnology, Pharmaceutical and Healthcare News
(MedPage Today) -- First PARP inhibitor to win breast cancer indication
Original Article: Olaparib OK'd for Metastatic Breast Ca with Mutated BRCA
NEXT ARTICLE
More From BioPortfolio on "Olaparib OK'd for Metastatic Breast Ca with Mutated BRCA"